drugset / Trial / NCT03296800

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

NCT03296800

Phase 1 Completed 48 enrolled Theracos
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin. The study is to evaluate how safe the study drug is and how well the study drug is tolerated when taken with probenecid, verapamil or rifampin.

Timeline

Start
2017-09-27
Primary completion
2017-12-06
Completion
2017-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexagliflozin Small molecule 20 mg
Subject Probenecid Small molecule 500 mg
Subject Rifampin Small molecule 600 mg
Subject Verapamil Other / unclassified 120 mg